JP2023512181A5 - - Google Patents
Info
- Publication number
- JP2023512181A5 JP2023512181A5 JP2022544181A JP2022544181A JP2023512181A5 JP 2023512181 A5 JP2023512181 A5 JP 2023512181A5 JP 2022544181 A JP2022544181 A JP 2022544181A JP 2022544181 A JP2022544181 A JP 2022544181A JP 2023512181 A5 JP2023512181 A5 JP 2023512181A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- agent according
- combination agent
- seq
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968121P | 2020-01-30 | 2020-01-30 | |
| US62/968,121 | 2020-01-30 | ||
| US202063011036P | 2020-04-16 | 2020-04-16 | |
| US63/011,036 | 2020-04-16 | ||
| PCT/US2021/015749 WO2021155180A1 (en) | 2020-01-30 | 2021-01-29 | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026072821A Division JP2026133428A (ja) | 2020-01-30 | 2026-04-24 | 癌を治療するためのｅｇｆｒ阻害剤とｒｏｒ１阻害剤の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512181A JP2023512181A (ja) | 2023-03-24 |
| JP2023512181A5 true JP2023512181A5 (enExample) | 2024-02-02 |
Family
ID=77079208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544181A Pending JP2023512181A (ja) | 2020-01-30 | 2021-01-29 | 癌を治療するためのｅｇｆｒ阻害剤とｒｏｒ１阻害剤の組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230070988A1 (enExample) |
| EP (1) | EP4097137A4 (enExample) |
| JP (1) | JP2023512181A (enExample) |
| KR (1) | KR20220140534A (enExample) |
| CN (1) | CN115485298A (enExample) |
| AU (1) | AU2021214581A1 (enExample) |
| CA (1) | CA3169455A1 (enExample) |
| TW (1) | TW202140016A (enExample) |
| WO (1) | WO2021155180A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4097137A4 (en) * | 2020-01-30 | 2024-04-17 | Oncternal Therapeutics, Inc. | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| WO2024123126A1 (ko) * | 2022-12-09 | 2024-06-13 | 재단법인대구경북과학기술원 | 올무티닙을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| HK1253507A1 (zh) * | 2015-05-18 | 2019-06-21 | Eureka Therapeutics, Inc. | 抗 ror1 抗体 |
| WO2017200016A1 (ja) * | 2016-05-17 | 2017-11-23 | 公益財団法人がん研究会 | Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬 |
| WO2018227023A1 (en) * | 2017-06-07 | 2018-12-13 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| TWI804499B (zh) * | 2017-06-23 | 2023-06-11 | 美商維洛斯生物公司 | Ror1抗體免疫接合物 |
| EP3645741A4 (en) * | 2017-06-25 | 2021-08-25 | Systimmune, Inc. | ANTI-4-1BB ANTIBODIES AND METHOD OF MANUFACTURING AND USING |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| EP4097137A4 (en) * | 2020-01-30 | 2024-04-17 | Oncternal Therapeutics, Inc. | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer |
-
2021
- 2021-01-29 EP EP21748091.2A patent/EP4097137A4/en active Pending
- 2021-01-29 TW TW110103582A patent/TW202140016A/zh unknown
- 2021-01-29 CN CN202180025836.5A patent/CN115485298A/zh active Pending
- 2021-01-29 JP JP2022544181A patent/JP2023512181A/ja active Pending
- 2021-01-29 AU AU2021214581A patent/AU2021214581A1/en active Pending
- 2021-01-29 US US17/759,681 patent/US20230070988A1/en active Pending
- 2021-01-29 CA CA3169455A patent/CA3169455A1/en active Pending
- 2021-01-29 KR KR1020227029753A patent/KR20220140534A/ko active Pending
- 2021-01-29 WO PCT/US2021/015749 patent/WO2021155180A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025109785A5 (enExample) | ||
| JP2024029049A5 (enExample) | ||
| RU2346702C2 (ru) | Применение антител к ctla-4 | |
| JP2021102627A5 (enExample) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2020103301A5 (enExample) | ||
| RU2014106671A (ru) | Варианты гуманизированных иммуномодулирующих моноклональных антител | |
| JP2020529863A5 (enExample) | ||
| JP2025092589A5 (enExample) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2018008949A5 (enExample) | ||
| RU2013104830A (ru) | Лечение рака при помощи направленных на мишень антител in vivo | |
| RU2013136172A (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP2015517300A5 (enExample) | ||
| US20150175712A1 (en) | Antagonist to an enzyme and/or a metabolite of the kynurenine pathway | |
| RU2019143101A (ru) | Новое анти-с-мет антитело и его применение | |
| JP2021532143A5 (enExample) | ||
| JP2023527937A5 (enExample) | ||
| JPWO2022270524A5 (enExample) | ||
| Yang et al. | A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues | |
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JP2024512574A5 (enExample) | ||
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JP2024020436A5 (enExample) |